Nemtabrutinib Evidence: Trial Results and Peer-Reviewed Publications

Hipa.ai Research · Source: PubMed & ClinicalTrials.gov / AACT · Last updated: May 26, 2026

The clinical evidence base for Nemtabrutinib comprises 3 peer-reviewed publications across 3 journals, 0 pivotal-trial primary-outcome rows reported to ClinicalTrials.gov, spanning indications including Leukemia, Lymphocytic, Chronic, B-Cell. Most recent publication: BRUIN 313 and 314 Trials Open the Door for Noncovalent Bruton Tyrosine Kinase Inhibition as Initial Therapy for Chronic Lymphocytic Leukemia., J Clin Oncol, 2026.

Top peer-reviewed publications

Curated set of pivotal-trial result papers and recent publications in high-tier journals.

First-in-Human Study of the Reversible BTK Inhibitor Nemtabrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia and B-Cell Non-Hodgkin Lymphoma.
Woyach JA, Stephens DM, Flinn IW, et al. · Cancer Discov · 2024
PubMed: PMID 37930156 · NCT03162536 · Leukemia, Lymphocytic, Chronic, B-Cell
Mining the Microenvironment for Therapeutic Targets in Chronic Lymphocytic Leukemia.
Kipps TJ · Cancer J · 2021
PubMed: PMID 34398557 · NCT03162536 · Leukemia, Lymphocytic, Chronic, B-Cell
BRUIN 313 and 314 Trials Open the Door for Noncovalent Bruton Tyrosine Kinase Inhibition as Initial Therapy for Chronic Lymphocytic Leukemia.
Davids MS · J Clin Oncol · 2026
PubMed: PMID 41363770 · NCT05624554 · Leukemia, Lymphocytic, Chronic, B-Cell

Publications by year

2021–2026: 3 publications.

2021

2024

2026

Publications by indication

Leukemia, Lymphocytic, Chronic, B-Cell (3)

BRUIN 313 and 314 Trials Open the Door for Noncovalent Bruton Tyrosine Kinase Inhibition as Initial Therapy for Chronic Lymphocytic Leukemia.
J Clin Oncol · 2026 · PMID 41363770 · NCT05624554
First-in-Human Study of the Reversible BTK Inhibitor Nemtabrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia and B-Cell Non-Hodgkin Lymphoma.
Cancer Discov · 2024 · PMID 37930156 · NCT03162536
Mining the Microenvironment for Therapeutic Targets in Chronic Lymphocytic Leukemia.
Cancer J · 2021 · PMID 34398557 · NCT03162536

Publications by journal

Cancer Discov1 paper
Cancer J1 paper
J Clin Oncol1 paper

All Nemtabrutinib publications (3)

2026 (1 paper)

BRUIN 313 and 314 Trials Open the Door for Noncovalent Bruton Tyrosine Kinase Inhibition as Initial Therapy for Chronic Lymphocytic Leukemia.
Davids MS · J Clin Oncol · 2026 · Derived
PubMed: PMID 41363770 · NCT05624554 · Leukemia, Lymphocytic, Chronic, B-Cell

2024 (1 paper)

First-in-Human Study of the Reversible BTK Inhibitor Nemtabrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia and B-Cell Non-Hodgkin Lymphoma.
Woyach JA, Stephens DM, Flinn IW, et al. · Cancer Discov · 2024 · Trial result
PubMed: PMID 37930156 · NCT03162536 · Leukemia, Lymphocytic, Chronic, B-Cell

2021 (1 paper)

Mining the Microenvironment for Therapeutic Targets in Chronic Lymphocytic Leukemia.
Kipps TJ · Cancer J · 2021 · Derived
PubMed: PMID 34398557 · NCT03162536 · Leukemia, Lymphocytic, Chronic, B-Cell

Sources and methodology

Publications: ctgov.study_references (PubMed PMIDs auto-attached by ClinicalTrials.gov to each trial), reference types RESULT, DERIVED, and BACKGROUND.
Per-arm outcome values: ctgov.outcome_measurements joined to ctgov.design_outcomes where outcome_type = 'PRIMARY', restricted to phase PHASE3 and PHASE2/PHASE3.
Publication metadata (title, journal, year, authors): PubMed E-utilities efetch.fcgi
Data freshness: Tue, 26 May 2026 17:55:11 GMT.

This page summarizes published evidence for general reference and does not constitute medical advice. For clinical decisions, consult the linked primary publications and your healthcare provider. Data sourced from PubMed and the ClinicalTrials.gov / AACT database maintained by the Clinical Trials Transformation Initiative (CTTI).